Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid... Hence, tirapazamine is solely activated in those hypoxic areas of solid tumors.
- Mechanism
- Curator reviewed
Extensive preclinical testing has established that the mechanism for the selective toxicity towards hypoxic cells is the result of a one-electron reduction of the parent molecule to a free radical species that interacts with DNA to produce single- and double-strand breaks and lethal chromosome aberrations. It has also shown activity when combined with fractionated irradiation and when combined with some chemotherapy agents, particularly cisplatin and carboplatin.
- Primary indication
- For the treatment of head and neck cancer.Curator reviewed
- Formula / weight
- C7H6N4O2 · 178.151 g/mol (avg)
- Code names
- SR-259075 · SR-4233 · WIN-59075
Resolves to
ORYDPOVDJJZGHQ-UHFFFAOYSA-NSMILESNC1=[N+]([O-])C2=C(C=CC=C2)[N+]([O-])=N1What you can answer from here — as of January 29, 2025
Which drugs share a target with Tirapazamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account